JACOBIO PHARMACEUTICALS GROUP CO., LTD.
加科思藥業集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 1167)

POSITIVE PROFIT ALERT

This announcement is made by JACOBIO PHARMACEUTICALS GROUP CO., LTD. (the "**Company**", together with its subsidiaries, the "**Group**") pursuant to Rule 13.09(2)(a) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Listing Rules**") and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

The board of directors of the Company (the "**Board**") is pleased to inform the shareholders of the Company (the "**Shareholders**") and potential investors that, based on a preliminary assessment on the unaudited consolidated management accounts of the Company for the six months ended June 30, 2026 (the "**Reporting Period**") and the information currently available to the Board, it is expected that the Company will record a net profit of not less than RMB600 million, as compared to the net loss of approximately RMB58.99 million for the six months ended June 30, 2025. This is the first time for the Company to achieve profits.

The turnaround from net loss to net profit of the Company during the Reporting Period was primarily attributable to a significant growth in revenue, with contributions from (i) the income generated from the strategic licensing collaboration with AstraZeneca AB for the global R&D, manufacture, and commercialization of JAB-23E73 (pan-KRAS) except for the People's Republic of China (excluding Hong Kong Special Administrative Region, the Macau Special Administrative Region, and Taiwan) and (ii) the income generated from the out-licensing and service agreements with Shanghai Allist Pharmaceuticals Co., Ltd. regarding the R&D, manufacture, and commercialization of 艾瑞凯® (glecirasib, KRAS G12C) and sitneprotafib (JAB-3312, SHP2) in the People's Republic of China. For details of the aforementioned licensing arrangements, please refer to the announcements of the Company dated December 21, 2025 and August 30, 2024.

As the Company is still in the process of finalizing the results of the Company for the Reporting Period, the information contained in this announcement is only based on the preliminary assessment made by the Board with reference to the Company's unaudited consolidated management accounts for the Reporting Period and the information currently available to the Board, which has neither been reviewed nor confirmed by the auditors of the Company or the audit committee of the Board. The actual results of the Company for the six months ended June 30, 2026 may differ from the information contained in this announcement and may be subject to adjustments. As such, the above figures are provided for Shareholders' and potential investors' reference only. Shareholders and potential investors are advised to read carefully the Company's interim results announcement for the Reporting Period which is expected to be published in August 2026.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
JACOBIO PHARMACEUTICALS GROUP CO., LTD.
Yinxiang WANG
Chairman

Hong Kong, August 10, 2026

As at the date of this announcement, the Board comprises Dr. Yinxiang WANG as Chairman and executive Director, Ms. Xiaojie WANG and Ms. Yunyan HU as executive Directors, Dr. Te-li CHEN as non-executive Director, and Dr. Ruilin SONG, Dr. Bai LU and Dr. Ge WU as independent non-executive Directors.